-- First of two Pivotal Efficacy Studies support future sNDA submission for Treatment of Pulmonary Anthrax -- Oral NUZYRA Tablets Produced in the U.S. as a Result of the Company's Onshoring Initiative ...

BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness in the ...

BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving ...

In the event of an attack with biological weapons, would the anthrax vaccine offer protection against pulmonary anthrax, or would rapid administration of antibiotics be more efficacious? —LAWRENCE ...

Given the possible severity of anthrax infection, early and fast diagnosis is key. InBios International, Inc., a developer of diagnostic tests for emerging infectious diseases and biothreats, has been ...

Oct. 16 -- Some of America's top biological warfare scientists are edging closer to a conclusion they've resisted since receiving word of the first anthrax infection in Florida — that the recent germ ...

First of two Pivotal Efficacy Studies support future sNDA submission for Treatment of Pulmonary Anthrax Oral NUZYRA Tablets Produced in the U.S. as a Result of the Company's Onshoring Initiative were ...

In the event of a biological weapons attack, would the anthrax vaccine offer protection against pulmonary anthrax, or would rapid administration of antibiotics be more efficacious? —LAWRENCE SHEDWICK, ...

BOSTON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of ...

KING OF PRUSSIA, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies ...